# A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Source: https://onco.cc/trials/nct06630234/  
OnCo record `nct06630234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DCC-3009 in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, now recruiting.

## Summary

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) is a phase 1/2 interventional study registered as NCT06630234 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2024-12-10 and due to reach its primary completion in 2028-05. Interventions recorded: DCC-3009.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06630234
- Phase: 1/2
- Setting: A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)
- Sponsor: Deciphera Pharmaceuticals, LLC
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06630234: https://clinicaltrials.gov/study/NCT06630234

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct06630234.json